A RANDOMIZED PHASE III TRIAL OF ADJUVANT THERAPY COMPARING DOXORUBICIN PLUS CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL WITH OR WITHOUT CARBOPLATIN FOR NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE TRIPLE-NEGATIVE INVASIVE BREAST CANCER
- Registry ID
- NRG-BR003
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NRG ONCOLOGY
- Start date
- 2016-02-08
- Last update
- 2015-08-05
Conditions
- BREAST CANCER
- BREAST CANCER METASTATIC TRIPLE NEGATIVE
Related clinical trials
- 68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
- A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
- A PHASE III, MULTISITE, RANDOMIZED, DOUBLE-BLIND TRIAL OF BNT327 IN COMBINATION WITH CHEMOTHERAPY VERSUS PLACEBO WITH CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY RECURRENT INOPERABLE OR METASTATIC TNBC DETERMINED INELIGIBLE FOR PD(L)1 THERAPY BASED ON PD-L1 NEGATIVE DISEASE
- A PHASE IB/II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY
EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF
GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN
COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN
PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC
ESTROGEN RECEPTOR-POSITIVE, HER2 NEGATIVE BREAST CANCER
WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6
INHIBITOR
- A PHASE 3 OPEN-LABEL RANDOMIZED STUDY ASSESSING THE EFFICACY AND
SAFETY OF RLY-2608 + FULVESTRANT VERSUS CAPIVASERTIB + FULVESTRANT AS TREATMENT FOR
PIK3CA-MUTANT HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR
2 NEGATIVE (HR+/HER2-) LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE OR PROGRESSION ON OR AFTER TREATMENT WITH A CDK4/6 INHIBITOR
View on source registry